European Pharmaceutical Review

NOVEMBER 28, 2024

This dual-layer certification process can create significant delays, as each framework involves extensive assessments for safety and performance under separate requirements specific to medical device and AI-specific criteria.

Government 105

Government Medical Safety Management 105

PM360

JANUARY 24, 2025

The use of medicines worldwide grew by 14% over the past five years, and is expected to grow an additional 12% by 2028. Some countries require local studies due to different safety and efficacy results. Navigating global regulations shouldnt be seen as a hurdle; its a competitive advantage for the brands that do it well.

Marketing 52

Marketing Pharma Healthcare Healthcare 52

PM360

SEPTEMBER 21, 2023

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.

Management 105

Management Manufacturing Sales Competition 105

Medico Reach

OCTOBER 17, 2022

million by 2028. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. The potential increase in industry competition could also spell trouble for some. Now, the demand for such equipment is on track to grow exponentially.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Pharmaceutical Technology

OCTOBER 28, 2022

The vaccine demonstrated a similar safety profile to Pfizer’s marketed 20-serotype shot Prevnar 20 at all assessed doses, and showed non-inferior efficacy. billion and $812 million in 2028. Competition in an increasingly heated market. VAX-24 has forecasted sales of $21 million in the same year. Further plans in the making.

Training 64

Training Marketing Competition FDA 64

Pharmaceutical Representative Training

JANUARY 29, 2025

These high prices are the result of multiple factors: theyre derived from living organisms making them sensitive and complex for both manufacturers and patients, research requires advanced technology to test for safety and effectiveness, and theyre in high demand without much competition. billion and $13 billion in 2023, respectively.

Marketing 52

Marketing Healthcare Healthcare Physicians 52

Pharmaceutical Technology

FEBRUARY 13, 2023

By this same virtue, PROTACs are able to degrade previously undruggable targets, which provides a major competitive advantage for this modality if shown to be true. GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028. with Calquence, 16% with Imbruvica, NCT02477696).

Competition 59

Competition Safety Patients Pharmaceutical 59